Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 10
22:07 2023
Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Non-Small-Cell Lung Cancer Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Non-Small-Cell Lung cancer pipeline landscape. It covers the Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Non-Small Cell Lung Cancer pipeline products in this space.

 

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
  • The leading companies working in the Non-Small Cell Lung Cancer Market include GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc., and others.
  • Promising Non-small cell lung cancer pipeline therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, and others.
  • August 2023: Regeneron Pharmaceuticals announced a study of Phase 2 clinical trials for Cemiplimab and BNT116. The study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a “study drug”, and together be called “study drugs” in this form. The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).
  • October 2023: NovoCure GmbH announced a study of Phase 2 Clinical Trials for Pembrolizumab (MK-3475) 200 mg. This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to those treated with pembrolizumab alone.

 

Request a sample and discover the recent advances in Non-Small Cell Lung Cancer Treatment Drugs @ Non-Small Cell Lung Cancer Pipeline Report

 

In the Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Small-Cell Lung cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Non-Small Cell Lung Cancer Overview

Non-small-cell lung cancer (NSCLC) is any type of epithelial lung cancer other than small-cell lung cancer (SCLC) and accounts for about 85% of all lung cancers. There are three kinds of NSCLC tumors: a) Adeno cancer starts in cells inside air sacs that make mucus and other substances, often in the outer parts of your lungs.

 

Find out more about Non-Small Cell Lung Cancer Therapeutics Assessment @ Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products

 

Non-Small Cell Lung Cancer Emerging Drugs Profile

  • AMG 510: Amgen
  • CMP 001: Cytos Biotechnology

 

Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the Non-Small Cell Lung Cancer pipeline therapies. The Non-Small Cell Lung Cancer companies which have their Non-Small-Cell Lung cancer (NSCLC) drug candidates in the mid to advanced stage, i.e.Phase I include, Amgen.

 

Learn more about the emerging Non-Small Cell Lung Cancer Pipeline Therapies @ Non-Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Non-Small Cell Lung Cancer Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc., and others.
  • Non-Small Cell Lung Cancer Pipeline Therapies- Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, and others.

 

Dive deep into rich insights for new drugs for Non-Small Cell Lung Cancer Treatment, Visit @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Late Stage Products (Pre Registration)
  9. AMG 510: Amgen
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Drug Name: Company Name
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. CMP 001: Cytos Biotechnology
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  19. Non-Small-Cell Lung cancer (NSCLC) Key Products
  20. Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
  21. Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
  22. Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
  23. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  24. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  25. Appendix

 

For further information on the Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Related Articles

Categories